Giulio Francia to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Giulio Francia has written about Drug Resistance, Neoplasm.
Connection Strength
0.929
-
Francia G, Emmenegger U, Kerbel RS. Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell. 2009 Jan 06; 15(1):3-5.
Score: 0.287
-
Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004 Aug; 24(15):6837-49.
Score: 0.211
-
Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 2017 08 01; 400:311-318.
Score: 0.126
-
Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest New Drugs. 2014 Feb; 32(1):47-59.
Score: 0.097
-
du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):904-16.
Score: 0.059
-
Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y, Kerbel RS. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther. 2005 Oct; 4(10):1484-94.
Score: 0.057
-
Orlandi P, Banchi M, Vaglini F, Carli M, Aringhieri S, Bandini A, Pardini C, Viaggi C, Lai M, Al? G, Ottani A, Vandini E, Guidi P, Bernardeschi M, La Rocca V, Francia G, Fontanini G, Pistello M, Frenzilli G, Giuliani D, Scarselli M, Bocci G. Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib. Biochem Pharmacol. 2024 01; 219:115952.
Score: 0.050
-
Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia. 2011 Jan; 13(1):40-8.
Score: 0.021
-
Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010 Nov; 12(11):928-40.
Score: 0.020